ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2020
COVID-19 in solid organ transplant recipients: Initial report from the US epicenter.
Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05116748 (Safety and Immunogenicity of the SARS-CoV2 Vaccine in Solid Organ Transplantation), which is not on this map. Cited by 495 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Immunogenicity of the SARS-CoV2 Vaccine in Solid Organ Transplantation (Lung and / or Liver) Adult Recipients
Who cites it
495 citing papers in PubMed, 6 syntheses or guidelines pooled it, 832 citations in OpenAlex.
- Value of Emerging and Existing Pre-prophylaxis and Therapeutic Options for COVID-19 in Transplant Recipients: A Systematic Review of Economic Evaluations.PharmacoEconomics - open · 2026Pooled it
- Donor heart selection: Evidence-based guidelines for providers.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2023Guideline
- COVID-19 and solid organ transplantation: Finding the right balance.Transplantation reviews (Orlando, Fla.) · 2022Pooled it
- Immunogenicity and Risk Factors Associated With Poor Humoral Immune Response of SARS-CoV-2 Vaccines in Recipients of Solid Organ Transplant: A Systematic Review and Meta-Analysis.JAMA network open · 2022Pooled it
- Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis.BMJ (Clinical research ed.) · 2022Pooled it
- Clinical characteristics and outcome of coronavirus disease 2019 infection in patients with solid organ transplants: A systematic review and meta-analysis.Journal of infection and public health · 2022Pooled it
- mRNA-1273 COVID-19 vaccine induces CD4+ T-cell responses among solid organ transplant recipients.Frontiers in immunology · 2025Trial
- Effect of neuro-linguistic programming on COVID-19 fear in kidney transplant patients: A randomized controlled study.Complementary therapies in clinical practice · 2022Trial
- Lessons learned: management of acute kidney injury during COVID-19.Renal failure · 2026Article
- Increased In-Hospital Mortality in Immunocompromised Individuals Hospitalized With COVID-19 During the Global Pandemic: A Multinational Cohort Study in the EuCARE Project.The Journal of infectious diseases · 2026Article
- Review
- Multiomic Immune Profiling of Pediatric Transplant Recipients Identifies Cell States Associated with Vaccine Response.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- Outcomes of immunocompromised and non-immunocompromised patients in the ICU diverge late in the pandemic.PloS one · 2026Article
- Immunosuppressed patients with COVID-19 pneumonia in ICU: clinical characteristics and factors influencing outcomes.Pneumonia (Nathan Qld.) · 2025Article
- An Offline SPE-LC-MS/MS Method for Simultaneous Quantification of Tacrolimus, Cyclosporine A, Kynurenine, Tryptophan, and Creatinine Using Volumetric Absorptive Microsampling Device Mitra.Therapeutic drug monitoring · 2025Article
- A Single-Center Retrospective Study on Early Treatment for COVID-19 in Solid Organ Transplant Recipients During the Omicron Era: Outcomes and SARS-CoV-2 Viral Kinetics.Microorganisms · 2025Article
- Corticosteroids in immunocompromised ICU patients with severe COVID-19: a multicenter retrospective study.Scientific reports · 2025Article
- Anxiety and Depressive Symptoms Post-COVID-19 Pandemic Onset in Solid Organ Transplant Recipients: Canadian Repeated Cross-Sectional Study.Journal of clinical medicine · 2025Article
- Early combined therapy for COVID-19 in immunocompromised patients: a promising approach against viral persistence and drug resistance.BMC infectious diseases · 2025Review
- Risk factors for mortality among kidney transplant recipients with COVID-19 in Saudi Arabia: a case-control study.BMC infectious diseases · 2025Article
435 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
26 authors at 2 institutions in 1 country.
Funding
Abstract
Solid organ transplant recipients may be at a high risk for SARS-CoV-2 infection and poor associated outcomes. We herein report our initial experience with solid organ transplant recipients with SARS-CoV-2 infection at two centers during the first 3 weeks of the outbreak in New York City. Baseline characteristics, clinical presentation, antiviral and immunosuppressive management were compared between patients with mild/moderate and severe disease (defined as ICU admission, intubation or death). Ninety patients were analyzed with a median age of 57 years. Forty-six were kidney recipients, 17 lung, 13 liver, 9 heart, and 5 dual-organ transplants. The most common presenting symptoms were fever (70%), cough (59%), and dyspnea (43%). Twenty-two (24%) had mild, 41 (46%) moderate, and 27 (30%) severe disease. Among the 68 hospitalized patients, 12% required non-rebreather and 35% required intubation. 91% received hydroxychloroquine, 66% azithromycin, 3% remdesivir, 21% tocilizumab, and 24% bolus steroids. Sixteen patients died (18% overall, 24% of hospitalized, 52% of ICU) and 37 (54%) were discharged. In this initial cohort, transplant recipients with COVID-19 appear to have more severe outcomes, although testing limitations likely led to undercounting of mild/asymptomatic cases. As this outbreak unfolds, COVID-19 has the potential to severely impact solid organ transplant recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.